Vor Biopharma Inc. (NASDAQ: VOR) is a Healthcare company (Biotechnology) with a market capitalization of $985M. The Maz Rating grades it against the other companies in its sector.
Vor Biopharma Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $18.18, Vor Biopharma Inc. trades at 0.1x trailing earnings, with an EV/EBITDA of 0.7. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -830.4%, return on invested capital of -38.5% and a free cash flow yield of -12.2%. On the balance sheet: a debt-to-equity ratio of -0.02 and a current ratio of 13.50. Over the past 52 weeks the share price ranged from $6.50 to $26.00, with a beta of 1.83.
Vor Biopharma Inc. does not currently pay a dividend.
13 Wall Street analyst ratings cover the stock: 10 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Vor Biopharma Inc. (VOR) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 41.9% / 30% · Interest income / Revenue 460700000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 41.9% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 460700000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 41.9% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 460700000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.15% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 97.2% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 460700000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 97.0% / 33.33% · (Cash+Recv) / Total Assets 97.0% / 33.33% · Interest income / Revenue 460700000.0% / 5% | Fail |
No. As of September 2026, Vor Biopharma Inc. (VOR) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Vor Biopharma Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 460700000.0% of each dividend: Vor Biopharma Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.